{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:41:37Z","timestamp":1777632097743,"version":"3.51.4"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.critrevonc.2022.103599","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T18:25:05Z","timestamp":1642616705000},"page":"103599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Practical treatment guidance for cancer-associated thrombosis \u2013 Managing the challenging patient: A consensus statement"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-475X","authenticated-orcid":false,"given":"Kathryn M.","family":"Musgrave","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieron","family":"Power","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8268-3268","authenticated-orcid":false,"given":"Mike","family":"Laffan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0309-3313","authenticated-orcid":false,"given":"James S.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1948-0513","authenticated-orcid":false,"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-5176","authenticated-orcid":false,"given":"Anthony","family":"Maraveyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.critrevonc.2022.103599_bib0005","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103599_bib0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/0897190019854578","article-title":"Investigation of direct-acting oral anticoagulants and the incidence of venous thromboembolism in patients weighing \u2265120 kg compared to patients weighing <120 kg","volume":"34","author":"Aloi","year":"2021","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0015","series-title":"Summary of Product Characteristics","author":"Apixaban","year":"2011"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0020","series-title":"80 Mg and 125 Mg Hard Capsulese","author":"Aprepitant Summary of Product Characteristics","year":"2018"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103599_bib0025","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1007\/s12325-020-01307-z","article-title":"Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review","volume":"37","author":"Ballestri","year":"2020","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103599_bib0030","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/cts.12580","article-title":"Drug-drug interaction study of apixaban with cyclosporine and tacrolimus in healthy volunteers","volume":"11","author":"Bashir","year":"2018","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103599_bib0035","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0038-1641150","article-title":"Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism - analysis of the CATCH Study","volume":"118","author":"Bauersachs","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103599_bib0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/bdd.411","article-title":"Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A","volume":"25","author":"Bekaii-Saab","year":"2004","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0045","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2018.06.015","article-title":"Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: clinical consequences","volume":"129","author":"Bellesoeur","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103599_bib0050","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40262-016-0403-6","article-title":"Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide","volume":"55","author":"Benoist","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103599_bib0055","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007901","article-title":"Risk stratification for bleeding complications in patients with venous thromboembolism: application of the HAS-BLED bleeding score during the first 6 months of anticoagulant treatment","volume":"7","author":"Brown","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103599_bib0060","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/jcph.1097","article-title":"Regional gastrointestinal absorption of apixaban in healthy subjects","volume":"58","author":"Byon","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2020.106682","article-title":"Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation","volume":"130","author":"Camporese","year":"2020","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0070","series-title":"Summary of Product Characteristics. 150mg and 500mg Tablets","author":"Capecitabine","year":"2008"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103599_bib0075","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/jth.14336","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors","volume":"17","author":"Carney","year":"2019","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103599_bib0080","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/rth2.12377","article-title":"Anticoagulation after intracranial hemorrhage in brain tumors: risk of recurrent hemorrhage and venous thromboembolism","volume":"4","author":"Carney","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103599_bib0085","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","article-title":"Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients","volume":"7","author":"Carrier","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0090","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jth.12338","article-title":"Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH","volume":"11","author":"Carrier","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103599_bib0095","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103599_bib0100","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jacc.2018.01.044","article-title":"Rivaroxaban with and without amiodarone in renal impairment","volume":"71","author":"Cheong","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.blre.2019.03.005","article-title":"Atrial fibrillation and cancer - an unexplored field in cardiovascular oncology","volume":"35","author":"Chu","year":"2019","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103599_bib0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103599_bib0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/10245330410001701585","article-title":"In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin","volume":"9","author":"Colburn","year":"2004","journal-title":"Hematology"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0120","series-title":"Fragmin\u00ae Solution for Injection","author":"Dalteparin Summary of Product Characteristics","year":"2021"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103599_bib0125","first-page":"739","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT\/PE studies","volume":"116","author":"Di Nisio","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103599_bib0130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","article-title":"Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study","volume":"126","author":"Donato","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0135","series-title":"2mg\/ml Solution for Injection","author":"Doxorubicin Summary of Product Characteristics","year":"2009"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103599_bib0140","first-page":"3209","article-title":"Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone","volume":"27","author":"Dubinsky","year":"2019","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0145","series-title":"Summary of Product Characteristics","author":"Edoxaban","year":"2015"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103599_bib0150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jcph.1702","article-title":"Discordance between Child-Pugh and National Cancer institute classifications for hepatic dysfunction: implications on dosing recommendations for oncology compounds","volume":"61","author":"Elmeliegy","year":"2021","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103599_bib0155","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11239-020-02179-4","article-title":"Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis","volume":"51","author":"Elshafei","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0160","series-title":"Direct Oral Anticoagulants (DOACs): Assessment Report. Committee for Medicinal Products for Human Use (CHMP)","author":"European Medicines Agency","year":"2020"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103599_bib0165","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103599_bib0170","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ndt\/gfy031","article-title":"A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation","volume":"34","author":"Feldberg","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103599_bib0175","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates","volume":"165","author":"Filppula","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0180","doi-asserted-by":"crossref","first-page":"j3782","DOI":"10.1136\/bmj.j3782","article-title":"Indications for anticoagulant and antiplatelet combined therapy","volume":"359","author":"Floyd","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103599_bib0185","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103599_bib0190","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International council for standardization in haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103599_bib0195","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11239-016-1465-x","article-title":"Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)","volume":"43","author":"Hakeam","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103599_bib0200","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s11239-020-02037-3","article-title":"The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding","volume":"49","author":"Hanigan","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103599_bib0205","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103599_bib0210","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1177\/1060028013504741","article-title":"Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?","volume":"47","author":"Hellwig","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0215","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2018.08.011","article-title":"B\u00fcller HR, van Es N. Direct oral anticoagulants in patients with liver cirrhosis: a systematic review","volume":"170","author":"Hoolwerf","year":"2018","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103599_bib0220","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfu080","article-title":"Anticoagulation in chronic kidney disease patients-the practical aspects","volume":"7","author":"Hughes","year":"2014","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0225","series-title":"Ifosfamide Injection 1g","author":"Ifosamide Summary of Product Characteristics","year":"2003"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0230","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2014.04.028","article-title":"Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis","volume":"134","author":"Ihaddadene","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0235","series-title":"400 Mg Film-coated Tablets","author":"Imatinib Summary of Product Characteristics","year":"2001"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0240","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study","volume":"157","author":"Jara-Palomares","year":"2017","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103599_bib0245","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE Disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103599_bib0250","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103599_bib0255","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","article-title":"Venous thromboembolism and prognosis in cancer","volume":"125","author":"Khorana","year":"2010","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103599_bib0260","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103599_bib0265","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103599_bib0270","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects","volume":"47","author":"Kubitza","year":"2007","journal-title":"J. Clin. Pharmacol."},{"issue":"14","key":"10.1016\/j.critrevonc.2022.103599_bib0275","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2013-04-460162","article-title":"Treatment of cancer-associated thrombosis","volume":"122","author":"Lee","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103599_bib0280","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103599_bib0285","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.critrevonc.2022.103599_bib0290","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.jacc.2019.04.052","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and liver disease","volume":"73","author":"Lee","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103599_bib0295","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1124\/dmd.30.7.814","article-title":"The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes","volume":"30","author":"Lindley","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0300","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/IJNRD.S105771","article-title":"Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations","volume":"10","author":"Lutz","year":"2017","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103599_bib0305","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3390\/cancers12082256","article-title":"Long-term treatment of cancer-associated thrombosis (CAT) beyond 6 months in the medical practice: USCAT, a 432-patient retrospective non-interventional study","volume":"12","author":"Mah\u00e9","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103599_bib0310","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jth.14752","article-title":"Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)","volume":"18","author":"Marshall","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103599_bib0315","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103599_bib0320","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00280-004-0799-9","article-title":"Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes","volume":"54","author":"Nallani","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0325","series-title":"50mg and 200mg Hard Capsules","author":"Nilotinib Summary of Product Characteristics","year":"2007"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0330","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/PPA.S79373","article-title":"Patients\u2019 experiences of LIving with CANcer-associated thrombosis: the PELICAN study","volume":"9","author":"Noble","year":"2015","journal-title":"Patient Prefer. Adherence"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103599_bib0335","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/rth2.12274","article-title":"Patient experience of living with cancer-associated thrombosis in Canada (PELICANADA)","volume":"4","author":"Noble","year":"2019","journal-title":"Pract. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0340","series-title":"5 mg\/ml Powder for Suspension for Infusion","author":"Paclitaxel Summary of Product Characteristics","year":"2008"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103599_bib0345","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3748\/wjg.v22.i3.1260","article-title":"Pharmacokinetic drug interactions in liver disease: an update","volume":"22","author":"Palatini","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103599_bib0350","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2141.2011.08826.x","article-title":"Anticoagulating obese patients in the modern era","volume":"155","author":"Patel","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103599_bib0355","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/00498250310001630215","article-title":"Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats","volume":"34","author":"Perloff","year":"2004","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103599_bib0360","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000042","article-title":"Cancer and liver cirrhosis: implications on prognosis and management","volume":"1","author":"Pinter","year":"2016","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103599_bib0365","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br. J. Surg."},{"issue":"19","key":"10.1016\/j.critrevonc.2022.103599_bib0370","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","article-title":"Oral anticoagulation in patients with liver disease","volume":"71","author":"Qamar","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103599_bib0375","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103599_bib0380","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1634\/theoncologist.2017-0473","article-title":"Use of direct oral anticoagulants in patients with cancer: practical considerations for the management of patients with nausea or vomiting","volume":"23","author":"Riess","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0385","series-title":"Summary of Product Characteristics","author":"Rivaroxaban","year":"2018"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103599_bib0390","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103599_bib0395","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/rth2.12111","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review","volume":"2","author":"Samuelson Bannow","year":"2018","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0400","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40164-019-0146-9","article-title":"Cabozantinib and apixaban: an hitherto unreported interaction","volume":"8","author":"Santini","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103599_bib0405","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jth.12955","article-title":"Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis","volume":"13","author":"Schulman","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2022.103599_bib0410","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/CMAR.S125864","article-title":"Considering renal risk while managing cancer","volume":"9","author":"Shahinian","year":"2017","journal-title":"Cancer Manag. Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103599_bib0415","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1200\/JOP.2017.022004","article-title":"Management of anticoagulation in patients with prostate cancer receiving enzalutamide","volume":"13","author":"Shatzel","year":"2017","journal-title":"J. Oncol. Pract."},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103599_bib0420","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-12-3214","article-title":"Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer institute Organ Dysfunction Working Group study","volume":"19","author":"Shibata","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103599_bib0425","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/dmd.108.024612","article-title":"Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2","volume":"37","author":"Shukla","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103599_bib0430","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1177\/1078155218801055","article-title":"Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein","volume":"25","author":"Shumaker","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103599_bib0435","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1345\/aph.1P354","article-title":"Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2","volume":"44","author":"Smith","year":"2010","journal-title":"Ann. Pharmacother."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103599_bib0440","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1111\/jth.14948","article-title":"Fixed dose rivaroxaban can be used in extremes of bodyweight: a population pharmacokinetic analysis","volume":"18","author":"Speed","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103599_bib0445","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0450","first-page":"63","article-title":"Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications","volume":"10","author":"Tahaineh","year":"2018","journal-title":"Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103599_bib0455","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"Upreti","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103599_bib0460","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11239-019-01847-4","article-title":"Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity","volume":"48","author":"van Oosterom","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0465","series-title":"240 Mg Film-coated Tablets","author":"Vemurafenib Summary of Product Characteristics","year":"2012"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0470","series-title":"Vinblastine Sulphate 1 mg\/ml Injection","author":"Vinblastine Summary of Product Characteristics","year":"2003"},{"key":"10.1016\/j.critrevonc.2022.103599_bib0475","series-title":"Navelbine 30mg Soft Capsule","author":"Vinorelbine Summary of Product Characteristics","year":"2005"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103599_bib0480","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjh.13556","article-title":"Guideline on aspects of cancer-related venous thrombosis","volume":"170","author":"Watson","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.critrevonc.2022.103599_bib0485","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1161\/CIRCULATIONAHA.115.020338","article-title":"Outcomes after vena cava filter use in noncancer patients with acute venous thromboembolism: a population-based study","volume":"133","author":"White","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103599_bib0490","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00228-014-1736-4","article-title":"Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation","volume":"70","author":"Yin","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103599_bib0495","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103599_bib0500","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J. Thromb. Haemost."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:43:14Z","timestamp":1760902994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":100,"alternative-id":["S1040842822000233"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103599","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical treatment guidance for cancer-associated thrombosis \u2013 Managing the challenging patient: A consensus statement","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103599"}}